Enochian Biosciences, Inc.
(NASDAQ : ENOB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Finance » Financial Conglomerates
symbolcompany%chnglast%shortavg$volume
CCitigroup, Inc. -0.02%53.331.0%$1637.94m
AXPAmerican Express Co. -0.38%105.011.7%$675.19m
VTIQVectoIQ Acquisition Corp. 8.29%33.970.0%$314.70m
PRUPrudential Financial, Inc. -0.40%63.461.4%$212.79m
EQHEquitable Holdings, Inc. -1.10%20.740.0%$64.40m
INGING Groep NV 0.42%7.270.2%$52.52m
FMCIForum Merger Ii Corp. 4.39%12.360.0%$22.02m
CNNECannae Holdings, Inc. -0.26%35.910.0%$16.02m
FBCFlagstar Bancorp, Inc. -2.38%28.351.3%$10.04m
IMVTImmunovant, Inc. 0.23%26.260.0%$9.64m
FPACFar Point Acquisition Corp. -0.10%10.270.0%$9.41m
ACTTAct II Global Acquisition Corp. 0.69%10.180.0%$6.66m
EFCEllington Financial, Inc. -1.67%10.620.1%$5.75m
SAMASchultze Special Purpose Acquisition Corp. -0.19%10.510.0%$4.95m
SHGShinhan Financial Group Co., Ltd. -4.05%28.190.0%$4.50m

Company Profile

Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA.